| CONTACT: Richard R. Current,
Vice President & CFO,
517/372-9200 |
LANSING, Mich., July 21, 2004 –
Neogen Corporation (Nasdaq: NEOG) today announced a 16% increase
in revenues for its 2004 fiscal year, which ended May 31, and a
continuation of the Company’s outstanding record of profitable
quarters from operations and revenue increases.
Despite non-recurring fourth quarter
expenses of $300,000 ($0.04 a share) to consolidate operations and
significantly cut future operational costs, Neogen was able to better
its net income per share compared to the previous year. The closing
of Neogen’s Chicago-area plant and consolidation of its veterinary
instruments business into other Company locations is expected to
save Neogen pre-tax approximately $400,000 to $500,000 annually,
beginning in the 2005 fiscal year.
FY 2004 revenues were $55,498,000,
up 16% from $47,685,000 in Neogen’s previous fiscal year.
Net income was $0.61 per share in FY 2004, compared to $0.60 in
the prior year. Neogen’s fourth quarter was the 45th consecutive
profitable quarter from operations for the Company, and the 50th
quarter of the past 54 quarters to show revenue increases on a year-to-year
comparison.
“We’re very pleased with
the year’s performance and also pleased with our direction
as we’ve sharpened our focus on the future,” said James
Herbert, Neogen’s president. “Not including the non-recurring
expenses related to the Chicago consolidation, we were able to increase
our operating income 18% on a revenue increase of 16%. That shows
a continuing return on our efforts to improve productivity and realize
overall cost reductions.”
Neogen’s fourth quarter revenues
improved 22% on a year-to-year comparison to $15,302,000. Quarterly
net income per share was $0.13 (after the non-recurring consolidation
charge) for the final FY 2004 three-month period. In the prior year
Neogen reported fourth quarter revenues of $12,527,000 and net income
of $0.16 per share.
“A great deal of manpower and
financial resources in 2004 went into positioning ourselves for
sustained growth for the future,” said Lon Bohannon, Neogen’s
chief operating officer. “We’ve made significant improvements
throughout our operations and still were able to improve on last
year’s exceptional operating results.”
In March, Neogen took action to consolidate
the Company’s Chicago Ideal Instruments operations into existing
operations in Lansing, Mich., and Lexington, Ky. The consolidation
was completed prior to Neogen’s year end on May 31. Ideal’s
inventories of finished goods, packaging, shipping, and customer
service were relocated to Neogen’s Lexington operations. Ideal’s
engineering, manufacturing, and quality control operations were
transferred to the Company’s Lansing facilities.
In FY 2004 Neogen moved into the food
and animal safety intervention arena with the purchase of Hacco
rodenticides and Hess & Clark agricultural disinfectants. Those
acquisitions are now in the final stages of integration.
In early FY 2004, Neogen opened a
25,000 square-foot food safety diagnostic manufacturing facility
near its Lansing headquarters. The new facility is intended to not
only improve manufacturing efficiencies, but also provide the space
to at least double the Company’s food safety diagnostic manufacturing
capacity. Later in the year, Neogen also purchased an additional
30,000 square-foot building adjacent to the Lansing campus. All
Company veterinary instrument manufacturing operations are now operating
from this facility in Lansing.
Also in 2004, Neogen’s Animal
Safety Division purchased and moved into an 80,000 square-foot facility
in Lexington, Ky. The new facility provides up to three times the
previous leased capacity, including space for all veterinary instrument
distribution from the closed Chicago facility. The move is also
expected to free up space at the Company’s separate Lexington
veterinary pharmaceutical plant to allow increased production and
improved operating efficiency for that group of products.
The year also saw the recently-renamed
Neogen Europe Ltd. (formerly Adgen, Ltd.) make significant inroads
into the European Union food safety testing market through the distribution
of U.S.-produced Neogen products, as well as its own plant disease
diagnostic tests. Neogen Europe’s sales improvements, along
with strong sales growth for GMO tests in South America, helped
increase international sales to 25% of total Company revenues, compared
to the prior year’s 20% of total revenues.
Neogen has recently introduced a number
of significant product improvements and product line extensions,
including:
-
Worldwide distribution rights to Colitag, an EPA-approved
water test for coliforms and E. coli. Industry estimates
place the growing worldwide rapid water testing market at about
$100 million.
-
AccuScan, the only lateral flow test reader available on
the market. AccuScan provides an easy method to objectively read,
store, and analyze results from Neogen’s Reveal line of lateral
flow tests for Listeria, E. coli O157:H7, Salmonella,
GMOs, mycotoxins, food allergens and ruminant material in animal
feed.
-
Reveal for Aflatoxin, a new lateral flow test format that
is the easiest and quickest test available for aflatoxin, a carcinogenic
mold toxin in grain. In a format similar to a home pregnancy test,
sample results are available in as little as two minutes.
-
The AccuPoint ATP Sanitation Monitoring System, which puts
the speed and convenience of ATP testing in a rugged, but lightweight
instrument that easily fits in the palm of a hand. AccuPoint is
available at a lower initial cost and is designed to be a more consistent,
reliable system that can be effectively operated by food industry
professionals to monitor cleanliness with virtually no user variability.
-
The GeneQuence Automated Pathogen Detection System, a fully
automated processing system that is capable of performing multiple
assays simultaneously. When combined with GeneQuence’s gene
probe assays, the system can quickly and accurately detect pathogens.
During FY 2004, Neogen earned its
third inclusion on Forbes Magazine’s annual list
of the 200 Best Small Companies in America, and was named to Fortune
Small Business’ list of the 100 fastest-growing, publicly-held
small businesses in America for the third straight year. Also in
FY 2004, Neogen’s Lansing operations joined its Lexington
operations in becoming fully ISO 9001:2000 certified. The certification
communicates to Neogen’s worldwide customer base that it understands
the quality standards customers expect, and is firmly committed
to consistently meeting those standards.
Neogen Corporation develops and markets
products dedicated to food and animal safety. The Company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.
NEOGEN
CORPORATION UNAUDITED SUMMARIZED
CONSOLIDATED OPERATING DATA
(In thousands, except for per share)
|
|
|
|
|
|
|
|
|
| Sales |
|
|
|
|
Food Safety
|
$6,798 |
$6,875 |
$27,567 |
$26,475 |
Animal Safety
|
8,504 |
5,652 |
27,931 |
21,210 |
| Total sales |
15,302 |
12,527 |
55,498 |
47,685 |
| Cost of sales |
7,982 |
5,757 |
27,989 |
21,763 |
| Gross margin |
7,320 |
6,770 |
27,509 |
25,922 |
| Operating
expenses
|
Sales & marketing
|
3,325 |
3,174 |
12,052 |
12,077 |
Administrative
|
1,600 |
1,005 |
5,023 |
4,146 |
Research & development
|
773 |
796 |
2,893 |
2,914 |
| Total operating expenses |
5,698 |
4,975 |
19,968 |
19,137 |
| Operating income |
1,622 |
1,795 |
7,541 |
6,785 |
| Other income (expense) |
(16) |
125 |
133 |
488 |
| Income before income
tax |
1,606 |
1,920 |
7,674 |
7,273 |
| Income tax |
535 |
638 |
2,575 |
2,486 |
| Net income |
$1,071 |
$1,282 |
$5,099 |
$4,787 |
| Net income
per diluted share |
$0.13 |
$0.16 |
$0.61 |
$0.60 |
| Other
information: |
Shares to calculate per share
|
8,544 |
8,062 |
8,377 |
7,985 |
Depreciation & amortization
|
497 |
191 |
1,404 |
1,136 |
Interest expense
|
30 |
- |
61 |
- |
Gross margin (% of sales)
|
47.8% |
54.0% |
49.6% |
54.4% |
Operating income (% of sales)
|
10.6% |
14.3% |
13.6% |
14.2% |
Revenue increase vs. FY 2003
|
22.2% |
|
16.4% |
|
Net income decrease/increase
vs. FY 2003
|
-16.4% |
|
6.5% |
|
All share and per share amounts give effect
to
5-for-4 split on Dec. 31, 2003 |
| NEOGEN CORPORATION UNAUDITED
SUMMARIZED CONSOLIDATED BALANCE SHEET DATA
(In thousands) |
|
31-May
2004 |
|
| Assets |
|
|
| Current assets |
|
|
Cash & securities
|
$1,696 |
$8,897 |
Accounts receivable
|
9,924 |
7,499 |
Inventories
|
12,374 |
9,840 |
Prepaid and other
|
2,282 |
1,735 |
| Total current assets |
26,276 |
27,971 |
| Property & equipment |
10,952 |
4,640 |
| Goodwill & other assets |
22,925 |
15,425 |
| Total assets |
60,153 |
48,036 |
|
|
| Liabilities
& Stockholders’ Equity
|
| Current liabilities |
5,656 |
5,763 |
|
| Long-term lines of
credit |
3,900 |
- |
|
| Other long-term liabilities |
2,755 |
871 |
|
| Equity |
47,842 |
41,402 |
|
| Total liabilities &
stockholders’ equity |
$60,153 |
$48,036 |
|
Certain portions of this news release
that do not relate to historical financial information constitute
forward-looking statements. These forward-looking statements are
subject to certain risks and uncertainties. Actual future results
and trends may differ materially from historical results or those
expected depending on a variety of factors listed in Management’s
Discussion and Analysis of Financial Condition and Results of Operations
in the Company’s most recently filed Form 10-K.
|